Living

Ebola Bundibugyo vaccine candidates could enter Phase 1 trials as early as July

By Reuters Reuters
FILE PHOTO: Congolese healthcare workers participate in an accelerated training session, at the newly built Samaritan's Purse International Relief tents, at the Scott Powell Memorial Ebola Treatment Center, as aid agencies intensify efforts to contain the Ebola outbreak caused by the Bundibugyo virus, in Bunia town, Ituri province, Democratic Republic of Congo, June 11, 2026. REUTERS/Gradel Muyisa Mumbere/File Photo
FILE PHOTO: Congolese healthcare workers participate in an accelerated training session, at the newly built Samaritan's Purse International Relief tents, at the Scott Powell Memorial Ebola Treatment Center, as aid agencies intensify efforts to contain the Ebola outbreak caused by the Bundibugyo virus, in Bunia town, Ituri province, Democratic Republic of Congo, June 11, 2026. REUTERS/Gradel Muyisa Mumbere/File Photo Gradel Muyisa Mumbere Reuters

NAIROBI/DAKAR - Lead vaccine candidates developed by Oxford University and Moderna against Ebola Bundibugyo, the deadly virus that has swept through eastern Democratic Republic of Congol, could enter Phase 1 trials as early as July, ⁠with field trials possible within several months, the head of the Coalition for Epidemic Preparedness Innovations, Richard Hatchett, said on Tuesday.

(Reporting by Anait Miridzhanian and Emma Farge; Editing by Alison Williams)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 16, 2026 at 9:14 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER